Fierce Biotech April 23, 2024
Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma.
The protein-focused artificial intelligence startup believes that its large language models can help extend the reach of CRISPR gene editing tools in the development of new therapies—and, to help prove it, it’s starting by making its work free to the public through an open-source license.
Profluent’s OpenCRISPR initiative aims to provide customizable gene editing proteins that are designed by AI from the ground up—molecules that take their inspiration from nature but have never been seen before.
Similar to other LLMs that ingest large amounts of text and track the most common patterns between words to construct a response, Profluent’s programs were trained...
Today's Sponsors
Today's Sponsor